Suppliers / MSN Pharmachem

MSN Pharmachem

India Updated 9 July 2026

MSN Pharmachem is an API manufacturer based in India. It holds 94 active US drug master files. Its most recent recorded inspection, by US FDA, closed on 21 April 2023 as VAI. Customs aggregates show $96.9M of exports covering 888 molecules to 62 destinations in 2025.

94
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
1
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 21 April 2023 VAI US FDA
  • 18 May 2018 NAI US FDA
  • 13 June 2014 NAI US FDA
  • 5 August 2011 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Sangareddy District, India 3006165229

What they file, and where

Molecule Regulators Docs
Moxifloxacin SFDA (Saudi Arabia), US FDA 7
Aprepitant US FDA 6
Lacosamide SFDA (Saudi Arabia), US FDA 6
Atorvastatin SFDA (Saudi Arabia), US FDA 5
Linagliptin SFDA (Saudi Arabia), US FDA 5
Lurasidone SFDA (Saudi Arabia), US FDA 5
Montelukast SFDA (Saudi Arabia), US FDA 5
Saxagliptin SFDA (Saudi Arabia), US FDA 5
Sitagliptin SFDA (Saudi Arabia), US FDA 5
Sumatriptan SFDA (Saudi Arabia), US FDA 5
Show all 30 molecules on file
Vortioxetine SFDA (Saudi Arabia), US FDA 5
Aripiprazole US FDA 4
Oseltamivir SFDA (Saudi Arabia), US FDA 4
Perindopril US FDA 4
Pregabalin US FDA 4
Rilpivirine US FDA 4
Vilazodone US FDA 4
Vildagliptin SFDA (Saudi Arabia), US FDA 4
Agomelatine US FDA 2
Aripiprazole Lauroxil US FDA 2
Atazanavir US FDA 2
Bisoprolol US FDA 2
Carbinoxamine US FDA 2
Darifenacin US FDA 2
Fesoterodine US FDA 2
Memantine US FDA 2
Milnacipran US FDA 2
Monelukast SFDA (Saudi Arabia) 2
Nebivolol US FDA 2
Ranolazine US FDA 2

Also appears on these molecule pages

Bisoprolol API Lacosamide API Linagliptin API Memantine API Montelukast API Moxifloxacin API Nebivolol API Perindopril API Saxagliptin API Sumatriptan API Vildagliptin API Atorvastatin API
Show 2 more molecule pages
Sitagliptin API Pregabalin API

Filings and GMP by regulator

Regulator Filings GMP certificates
CDSCO (India) 1 None

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $21.2M 31
2025 Not reported $96.9M 62
2024 Not reported $86.3M 53
2023 Not reported $70.6M 57

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. MSN Pharmachem comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 1 active litigation matter is on record.
  • The most recent inspection outcome was VAI, on 21 April 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
Customs aggregates
Export values, molecule and destination counts